Dartmouth Medicine HomeCurrent IssueAbout UsContact UsSearchPodcasts

PDF Version   Printer-Friendly Version


Memorable findings from imaging study

It's unnerving but normal for people to have occasional memory lapses as they get older. Yet some people insist that their forgetfulness is more serious than such "senior moments," even though they do fine on memory performance tests.

MRI scans tell a different story, however. They can detect brain abnormalities in people with these perceived "cognitive complaints"—those who, "on detailed clinical interviews and questionnaires, . . . really feel their memory and other cognitive functions are showing changes," says Andrew Saykin, Psy.D., a professor of psychiatry and of radiology. He reported this unexpected finding, based on a study of 120 older adults, at the Ninth International Conference on Alzheimer's Disease and Related Disorders.

"I thought at first if we saw complaints it would be associated with depression, because people who are depressed tend to feel their cognitive function isn't very ef- ficient," Saykin says. After excluding subjects with clinically significant depression, "it turned out that we were looking at something very specific to the memory system and that we found neural correlates for what people were telling us."


Andy Saykin uses imaging to diagnose dementias.

A combination of anatomic and functional MRI, or magnetic resonance imaging, can detect changes in the brains of people with diagnosed memory problems —from mild cognitive impairment (MCI) to Alzheimer's disease. Typically, the hippocampus, the walnut-sized part of the brain that is critical in learning and memory, begins to atrophy in early stages of cognitive disorders. Functional MRI, which maps changes in blood oxygenation during brain activity, showed that fewer brain cells are activated during memory exercises in people who are cognitively impaired than in people whose memory is normal. Subjects with "cognitive complaints" did well on memory tests, but their brains showed changes characteristic of MCI: atrophy of the hippocampus and reduced signaling in the frontal lobes.

Early: The finding may mean the cognitive complaint group could benefit from early intervention for Alzheimer's. About 50% of people with MCI go on to develop Alzheimer's or another dementia, says Saykin, though it's too soon to tell what percentage of those with "cognitive complaints" will do so.

In a different study—this one with only 18 patients, nine of them cognitively healthy and nine diagnosed with MCI —Saykin tested a drug called donepezil. While lying in an MRI scanner, subjects take a test that involves listening to a string of consonants and pressing a button when they hear certain patterns. They take the test without the drug and again after being on it for 10 weeks. "What we found was that in comparison to the control group, the people on drug basically were able to activate their frontal lobes," says Saykin, and that "correlated with better cognitive task performance."

In addition, data from a large trial suggests that the medication can delay the transition from MCI to Alzheimer's.

But while all the results are promising, Saykin cautions that much more study is needed.

—Laura Stephenson Carter

If you'd like to offer feedback about this article, we'd welcome getting your comments at DartMed@Dartmouth.edu.

This article may not be reproduced or reposted without permission. To inquire about permission, contact DartMed@Dartmouth.edu.

Back to Table of Contents

Dartmouth Medical SchoolDartmouth-Hitchcock Medical CenterWhite River Junction VAMCNorris Cotton Cancer CenterDartmouth College